Lataa...
Impact of continued administration of tolvaptan on cirrhotic patients with ascites
BACKGROUND: The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic patients with ascites. We investigated the outcome of long-term treatment. METHODS: This was a single-center retrospective study. Overall, 170 cirrhotic patients (95 males, median age 63 years) were enrolled and...
Tallennettuna:
| Julkaisussa: | BMC Pharmacol Toxicol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6299627/ https://ncbi.nlm.nih.gov/pubmed/30563565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-018-0277-3 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|